AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-3.67%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$639M
AUM Growth
+$639M
(-0.21%)
Cap. Flow
+$95.5M
Cap. Flow
% of AUM
14.95%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
109
New
20
Increased
27
Reduced
17
Closed
13
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 2 |
Travere Therapeutics
TVTX
|
$15.6M |
| 3 |
Protagonist Therapeutics
PTGX
|
$13.1M |
| 4 |
Nuvalent
NUVL
|
$12.4M |
| 5 |
Mineralys Therapeutics
MLYS
|
$11.9M |
Top Sells
| 1 |
Arvinas
ARVN
|
$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$10.3M |
| 3 |
Soleno Therapeutics
SLNO
|
$5.72M |
| 4 |
Arrowhead Research
ARWR
|
$5.64M |
| 5 |
Spyre Therapeutics
SYRE
|
$5.53M |
Sector Composition
| 1 | Healthcare | 90.82% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $44.6M | 4.25% | 1,328,175 +166,938 | +14% | +$5.6M |
|
2
Apogee Therapeutics
APGE
$2.17B
| $43M | 4.1% | 1,151,199 +219,471 | +24% | +$8.2M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $39M | 3.73% | 615,000 -45,000 | -7% | -$2.86M |
|
4
Arcellx
ACLX
$3.85B
| $34.8M | 3.32% | 530,000 +105,000 | +25% | +$6.89M |
|
5
Alkermes
ALKS
$4.78B
| $33M | 3.15% | 1,000,000 -100,000 | -9% | -$3.3M |
|
|
6
Nuvalent
NUVL
$5.52B
| $32.6M | 3.11% | 460,000 +175,000 | +61% | +$12.4M |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $26.5M | 2.53% | 80,000 -2,500 | -3% | -$828K |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.25B
| $22.2M | 2.12% | 1,546,662 +450,738 | +41% | +$6.48M |
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $21.5M | 2.05% | 1,400,000 | – | – |
|
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $19.3M | 1.85% | 400,000 +270,000 | +208% | +$13.1M |
|
|
11
Travere Therapeutics
TVTX
$1.56B
| $19.2M | 1.83% | 1,070,000 +870,000 | +435% | +$15.6M |
|
|
12
Mineralys Therapeutics
MLYS
$1.03B
| $17.5M | 1.67% | 1,100,000 +750,000 | +214% | +$11.9M |
|
|
13
SPDR S&P 500 ETF Trust
SPY
$658B
| $16.8M | 1.6% | +30,000 | New | +$16.8M |
|
14
Wave Life Sciences
WVE
$1.53B
| $14.7M | 1.41% | 1,825,000 +325,000 | +22% | +$2.63M |
|
15
Merus
MRUS
$4.98B
| $13.6M | 1.29% | 321,962 -67,279 | -17% | -$2.83M |
|
16
Axsome Therapeutics
AXSM
$6.05B
| $11.7M | 1.11% | 100,000 +25,000 | +33% | +$2.92M |
|
17
Establishment Labs
ESTA
$1.2B
| $11.4M | 1.09% | 280,000 +555 | +0.2% | +$22.6K |
|
18
Insmed
INSM
$28.8B
| $10.7M | 1.02% | 140,000 +90,000 | +180% | +$6.87M |
|
19
BridgeBio Pharma
BBIO
$9.89B
| $10.4M | 0.99% | 300,000 +100,000 | +50% | +$3.46M |
|
20
Nurix Therapeutics
NRIX
$714M
| $9.63M | 0.92% | 810,669 -129,414 | -14% | -$1.54M |
|
21
Vera Therapeutics
VERA
$1.38B
| $8.53M | 0.81% | 355,143 -69,857 | -16% | -$1.68M |
|
22
Trevi Therapeutics
TRVI
$883M
| $7.86M | 0.75% | +1,250,000 | New | +$7.86M |
|
|
23
Spyre Therapeutics
SYRE
$996M
| $7.77M | 0.74% | 481,678 -342,650 | -42% | -$5.53M |
|
24
Immunovant
IMVT
$2.56B
| $7.35M | 0.7% | 430,000 +330,000 | +330% | +$5.64M |
|
25
NewAmsterdam Pharma
NAMS
$2.71B
| $6.65M | 0.63% | 325,000 -100,000 | -24% | -$2.05M |
|